A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis

被引:53
作者
Ali, F. M. [1 ]
Cueva, A. C. [1 ,2 ]
Vyas, J. [1 ]
Atwan, A. A. [1 ]
Salek, M. S. [3 ,4 ]
Finlay, A. Y. [1 ]
Piguet, V. [1 ]
机构
[1] Cardiff Univ, Sch Med, Div Infect & Immun, Dept Dermatol & Acad Wound Healing, 3rd Floor,Glamorgan House,Heath Pk, Cardiff CF14 4XN, S Glam, Wales
[2] Ctr Piel, Quito, Ecuador
[3] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England
[4] Inst Medicines Dev, Cardiff, S Glam, Wales
关键词
SEVERE PLAQUE PSORIASIS; TO-SEVERE PSORIASIS; PATIENT-REPORTED OUTCOMES; PLACEBO-CONTROLLED TRIAL; CLOBETASOL PROPIONATE 0.05-PERCENT; NARROW-BAND UVB; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; DIPROPIONATE SCALP FORMULATION; DAILY CALCIPOTRIOL OINTMENT; ULTRAVIOLET-B PHOTOTHERAPY;
D O I
10.1111/bjd.14788
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Planners of interventional studies in psoriasis face the dilemma of selecting suitable quality-of-life (QoL) measures. Systematic reviews have the potential of identifying psychometrically sound measures in a given therapeutic area, while guiding the development of practice guidelines. The aim of this systematic review was to generate evidence of the use of QoL instruments in randomized controlled trials (RCTs) for interventions in psoriasis. The methodology followed the PRISMA guidelines. Six databases were searched with 388 search terms. Abstracts of articles were reviewed independently by two assessors, and a third adjudicator resolved any opinion differences. Risk of bias was assessed using the Jadad scale. Of 3646 screened publications, 99 articles (100 trials) met the eligibility criteria for inclusion, describing research on 33 215 patients. Thirty-three trials tested topical therapy, 18 systemic, 39 biologics, nine phototherapy and 10 other interventions. The Dermatology Life Quality Index (DLQI) was the most commonly used QoL instrument (83 studies, 83%), followed by the 36-Item Short Form Survey (SF-36) (31, 31%), EuroQoL-5D (EQ-5D) (15, 15%), Psoriasis Disability Index (14, 14%) and Skindex (five, 5%). There was widespread inconsistency in the way that QoL data were reported. Of the 100 trials identified, 37 reported minimal clinically important difference (MCID): 32 for DLQI, 10 for SF-36 and six for EQ-5D. QoL measurement is increasingly being reported in RCTs of psoriasis. Formal guidelines are needed for assessment and publishing of QoL data. Researchers should consider whether MCID information is available, and development of MCID data should be encouraged.
引用
收藏
页码:577 / 593
页数:17
相关论文
共 190 条
[1]   Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: A controlled comparison with calcipotriene (calcipotriol) cream [J].
Alora-Palli M.B. ;
Perkins A.C. ;
Van Cott A. ;
Kimball A.B. .
American Journal of Clinical Dermatology, 2010, 11 (4) :275-283
[2]  
[Anonymous], 2000, DERMATOL PSYCHOSOM
[3]  
[Anonymous], 2008, EXP REV DERM, DOI 10.1586/17469872.3.6.657
[4]  
[Anonymous], 2002, Br J Dermatol
[5]   Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study [J].
Asahina, Akihiko ;
Nakagawa, Hidemi ;
Etoh, Takafumi ;
Ohtsuki, Mamitaro .
JOURNAL OF DERMATOLOGY, 2010, 37 (04) :299-310
[6]   Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study [J].
Asawanonda, Pravit ;
Nateetongrungsak, Yaowalak .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (06) :1013-1018
[7]   Administration of DAB389IL-2 to patients with recalcitrant psoriasis:: A double-blind, phase II multicenter trial [J].
Bagel, J ;
Garland, WT ;
Breneman, D ;
Holick, M ;
Littlejohn, TW ;
Crosby, D ;
Faust, H ;
Fivenson, D ;
Nichols, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (06) :938-944
[8]  
Baker EL, 2012, DERMATOLOGY THER, V2, DOI 10.1007/s13555-012-0009-3
[9]   Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) [J].
Barker, J. ;
Hoffmann, M. ;
Wozel, G. ;
Ortonne, J. -P. ;
Zheng, H. ;
van Hoogstraten, H. ;
Reich, K. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) :1109-1117
[10]   The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results [J].
Basra, M. K. A. ;
Fenech, R. ;
Gatt, R. M. ;
Salek, M. S. ;
Finlay, A. Y. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (05) :997-1035